NCT02300844View on ClinicalTrials.gov

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 1, 2014

Primary Completion Date

March 21, 2016

Study Completion Date

March 21, 2016

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

NNC0174-0833

"Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated."

DRUG

placebo

Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.

Trial Locations (1)

66212

Novo Nordisk Investigational Site, Overland Park

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY